Leap Therapeutics, Inc. , a biotechnology company developing targeted and immuno-oncology therapeutics, today announced the completion of its merger with Macrocure Ltd , with Macrocure becoming a wholly-owned subsidiary of Leap. Leap will be listed on The Nasdaq Global Market under the symbol “LPTX” and expects to begin trading on Tuesday, January 24, 2017.